scholarly journals Benign Clinical and Epidemiological Outcomes-Associated Factors of COVID-19 from a Solved Epidemic with a Low Case Fatality Rate

2020 ◽  
Author(s):  
Gang Hu ◽  
Jian Liu ◽  
Peng Yuan He ◽  
Li Juan Ouyang ◽  
Bao Jia Zou ◽  
...  
Keyword(s):  
Associated Factors ◽  
Bacterial Infections ◽  
Case Fatality Rate ◽  
Secondary Infection ◽  
Antiviral Treatment ◽  
Disease Onset ◽  
Case Fatality ◽  
Fatality Rate ◽  
Treatment And Prevention ◽  
Epidemic Area

Abstract Background: Since December 2019, COVID-19 has been confirmed in more than18.8 million patients and leads to 0.70 million deaths worldwide. The mortality and disease severity predictors of COVID-19 have been investigated in many studies. However, they are based on early or partial datasets from high epidemic areas. Here, we retrospect benign clinical and epidemiological outcomes-associated factors from a solved epidemic in a low epidemic area. Methods: All 98 laboratory-confirmed COVID-19 patients in a local epidemic (Zhuhai, China) from January 17, 2020 to March 10, 2020 were enrolled. Data were updated until all patients having final outcomes. Results: Patients were all hospitalized. The case fatality rate was 1.0%. There were no local secondary infection cases. The median age was 46.3 years. Underlying diseases were found in 33.7% patients. The severe/critical rate was 19.4%. The mean period from disease onset to admission was 4.4 days. Compared with serious/critical cases, mild/common cases on admission were much younger, lacks of comorbidities and normal in functions of vital organs and indicators of secondary bacterial infections. The lymphocyte counts in serious/critical cases began to be significantly lower 3 days before their identification dates. The absence of lymphopenia before the eighth day from disease onset can exclude the possibility of 78.5% to be serious/critical ill. Most patients (88.8%) received antiviral treatments. Early antiviral treatment significantly shortened the viral RNA-negative conversion time. The delayed antiviral treatment was associated with critical patients.Conclusions: Younger age, lack of aging-related diseases and early hospitalization of all patients to conduct antiviral treatment and prevention of secondary epidemic were the important benign clinical and epidemiological outcomes-associated factors of COVID-19. In combating COVID-19, the active intervention strategies are crucial in low epidemic areas and the continuous monitoring of lymphocytes may be useful to sort patients reasonably in high epidemic areas.

scholarly journals Clinical characteristics of 50466 patients with 2019-nCoV infection

2020 ◽  
Author(s):  
Pengfei Sun ◽  
Shuyan Qie ◽  
Zongjan Liu ◽  
Jizhen Ren ◽  
Jianing Xi
Keyword(s):  
Case Fatality Rate ◽  
Clinical Characteristics ◽  
Muscle Soreness ◽  
Meta Analysis ◽  
Case Fatality ◽  
Cochrane Library ◽  
Fatality Rate ◽  
Treatment And Prevention ◽  
Abnormal Chest ◽  
Number Of Patients

AbstractObjectiveWe aim to summarize reliable evidences of evidence-based medicine for the treatment and prevention of the 2019 novel coronavirus (2019-nCoV) by analyzing all the published studies on the clinical characteristics of patients with 2019-nCoV.MethodsPubMed, Cochrane Library, Embase, and other databases were searched. Several studies on the clinical characteristics of 2019-nCoV infection were collected for Meta-analysis.ResultsTen studies were included in Meta-analysis, including a total number of 50466 patients with 2019-nCoV infection. Meta-analysis shows that, among these patients, the incidence of fever was 89.1%, the incidence of cough was 72.2%, and the incidence of muscle soreness or fatigue was 42.5%. The incidence of acute respiratory distress syndrome (ARDS) was 14.8%, the incidence of abnormal chest computer tomography (CT) was 96.6%, the percentage of severe cases in all infected cases was 18.1%, and the case fatality rate of patients with 2019-nCoV infection was 4.3%.ConclusionFever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination. Several people have muscle soreness or fatigue as well as ARDS. Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients. The case fatality rate of patients with 2019-nCoV infection is lower than that of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).

scholarly journals Clinical factors adversely affecting early outcome after brain infarction

1994 ◽  
Vol 52 (2) ◽  
pp. 153-160 ◽  
Author(s):  
Charles André ◽  
Sérgio A. P. Novis
Keyword(s):  
Case Fatality Rate ◽  
Brain Infarction ◽  
Univariate Analysis ◽  
Disease Onset ◽  
Case Fatality ◽  
Large Artery ◽  
Fatality Rate ◽  
Babinski Sign ◽  
Death Risk ◽  
History Of

PURPOSE AND METHODS: One-hundred-and-nine consecutive patients admitted during the acute phase of a CT-confirmed brain infarction (BI) were studied. Putative adverse influence of demographic and stroke risk factors, previous medical history, clinical presentation, initial and follow-up neurological examination, initial general evaluation, laboratory findings, chest X-ray and electrocardiographic findings, treatment, and topography and etiology of the ischemic insult was analysed. The end-point for assessment was early death (within 30 days). Statistical analysis was performed with univariate analysis and multiple regression. RESULTS: The main adverse factors related to an increased death risk during the first 30 days were, in decreasing order of importance: coma 48-72 hours after admission; stroke occuring in already hospitalized patients; Babinski sign on admission; minor degrees of impairment of consciousness 48-72 hours after admission; stroke related to large artery atherothrombosis and to embolism; a history of early impairment of consciousness; cardiac failure on admission. In 53 lucid patients on admission, only a history of congestive heart failure (CHF) was associated with a reduced survival rate. In 56 patients with impaired consciousness, the presence of a Babinski sign increased death risk, but the main factor predicting a high case-fatality rate was the persistence of consciousness disturbances after48-72 hours. CONCLUSIONS: The presence of impairment of consciousness, especially coma, 2-3 days after disease onset, and a history of CHF greatly increase the early case fatality rate in patients with acute BI presenting with or without consciousness disturbances at admission, respectively. The use of a prognostic algorythm considering these few variables seems to predict the approximate 30-day fatality rates.

Development research that contributes to saving lives of patients with severe fever with thrombocytopenia syndrome (SFTS)

Impact ◽  
2021 ◽  
Vol 2021 (8) ◽  
pp. 38-40
Author(s):  
Masayuki Saijo ◽  
Shigeru Morikawa ◽  
Tadaki Suzuki ◽  
Toru Takahashi ◽  
Ken Maeda ◽  
...  
Keyword(s):  
Case Fatality Rate ◽  
Medical Center ◽  
Case Fatality ◽  
Antiviral Agent ◽  
Fatality Rate ◽  
Viral Haemorrhagic Fever ◽  
Treatment And Prevention ◽  
Working Together ◽  
Relationship Of ◽  
Severe Fever

Severe fever with thrombocytopaenia syndrome (SFTS) is a tick-borne viral haemorrhagic fever with a high case fatality rate. Clinicians, veterinarians and scientists are working together to elucidate its pathophysiology and develop effective vaccines and treatments. The work is led by Dr Masayuki Saijo from the National Institute of Infectious Diseases (NIID) and also involves researchers from Yamaguchi University, Ehime University and Yamaguchi Grand Medical Center. The team is investigating the maintenance of the SFTS virus in nature by exploring the relationship of the virus between animals and ticks and the researchers are also working to clarify the pathophysiology of the disease, which will lead to the development of diagnostics, specific treatments and additional treatments and contribute to the further development of a vaccine. The researchers believe that a 'one health' approach to tackling SFTS is crucial, which is why they are tackling human and animal treatment and prevention in parallel. Favipiravir is an antiviral agent developed by Dr Yosuke Furuta from Toyama Chemicals and is the primary candidate for treatment. The team believes that if favipiravir can be administered to patients in the early stages of SFTS, this will reduce the case fatality rate of the disease. So far, the team has developed two recombinant vaccine candidates for SFTS that have so far demonstrated no major adverse effects. The researchers plan to develop other types of vaccines that will be safe for humans and animals.

scholarly journals Benign clinical and epidemiological outcomes-associated factors of COVID-19 from a solved epidemic with a low case fatality rate

2020 ◽  
Vol 7 (1) ◽  
Author(s):  
Gang Hu ◽  
Jian Liu ◽  
Peng Yuan He ◽  
Li Juan Ouyang ◽  
Bao Jia Zou ◽  
...  
Keyword(s):  
Associated Factors ◽  
Case Fatality Rate ◽  
Case Fatality ◽  
Fatality Rate

scholarly journals Finding the real COVID-19 case-fatality rates for SAARC countries

2020 ◽  
Author(s):  
Md. Rafil Tazir Shah ◽  
Tanvir Ahammed ◽  
Aniqua Anjum ◽  
Anisa Ahmed Chowdhury ◽  
Afroza Jannat Suchana
Keyword(s):  
Sri Lanka ◽  
South Asian ◽  
Case Fatality Rate ◽  
Regional Cooperation ◽  
Disease Onset ◽  
Case Fatality ◽  
Fatality Rate ◽  
Outcome Bias ◽  
Reporting Rates ◽  
Survival Interval

AbstractCrude case fatality rate (CFR) is the most accurate when the pandemic is over. Adjustments to the crude CFR measure can better explain the pandemic situation by improving the CFR estimation. However, no study has thoroughly investigated COVID-19 adjusted CFR of the South Asian Association for Regional Cooperation (SAARC) countries. In this study, we estimated both survival interval and underreporting adjusted CFR of COVID-19 for the SAARC countries and observed the CFR changes due to the imposition of fees on COVID-19 tests in Bangladesh. Using the daily records up to 9th October, we implemented a statistical method to remove both the bias in crude CFR, i.e., the delay between disease onset and outcome bias and due to asymptomatic or mild symptomatic cases, reporting rates lower than 50% (95% CI: 10%-50%) bias. According to our findings, Afghanistan had the highest CFR, followed by Pakistan, India, Bangladesh, Nepal, Maldives, and Sri Lanka. Our estimated crude CFR varied from 3.71% to 0.29%, survival interval adjusted CFR varied from 3.77% to 0.3% and further underreporting adjusted CFR varied from 1.1% to 0.08%. We have also found that crude CFR increased from 1.261% to 1.572% after imposing the COVID-19 test fees in Bangladesh. Therefore, the authorities of countries with higher CFR should be looking for strategic counsel from the countries with lower CFR to equip themselves with the necessary knowledge to combat the pandemic. Moreover, caution is needed to report the CFR.

scholarly journals Case fatality rate and associated factors in patients with 22q11 microdeletion syndrome: a retrospective cohort study

BMJ Open ◽  
2014 ◽  
Vol 4 (11) ◽  
pp. e005041 ◽  
Author(s):  
Gabriela M Repetto ◽  
M Luisa Guzmán ◽  
Iris Delgado ◽  
Hugo Loyola ◽  
Mirta Palomares ◽  
...  
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Associated Factors ◽  
Case Fatality Rate ◽  
Case Fatality ◽  
Fatality Rate ◽  
Microdeletion Syndrome

Impact of hydroxychloroquin/azithromycin protocol on COVID-19 case-fatality rate reduction in Algeria. (Preprint)

2020 ◽  
Author(s):  
Ahmed Youssef Kada
Keyword(s):  
Case Fatality Rate ◽  
Doubling Time ◽  
Case Fatality ◽  
World Health ◽  
Fatality Rate ◽  
Therapeutic Protocol ◽  
First Case ◽  
The World ◽  
The Impact ◽  
At Home

BACKGROUND Covid-19 is an emerging infectious disease like viral zoonosis caused by new coronavirus SARS CoV 2. On December 31, 2019, Wuhan Municipal Health Commission in Hubei province (China) reported cases of pneumonia, the origin of which is a new coronavirus. Rapidly extendable around the world, the World Health Organization (WHO) declares it pandemic on March 11, 2020. This pandemic reaches Algeria on February 25, 2020, date on which the Algerian minister of health, announced the first case of Covid-19, a foreign citizen. From March 1, a cluster is formed in Blida and becomes the epicentre of the coronavirus epidemic in Algeria, its total quarantine is established on March 24, 2020, it will be smoothly alleviated on April 24. A therapeutic protocol based on hydroxychloroquine and azithromycin was put in place on March 23, for complicated cases, it was extended to all the cases confirmed on April 06. OBJECTIVE This study aimed to demonstrate the effectiveness of hydroxychloroquin/azithromycin protocol in Algeria, in particular after its extension to all patients diagnosed COVID-19 positive on RT-PCR test. We were able to illustrate this fact graphically, but not to prove it statistically because the design of our study, indeed in the 7 days which followed generalization of therapeutic protocol, case fatality rate decrease and doubling time increase, thus confirming the impact of wide and early prescription of hydroxychloroquin/azithromycin protocol. METHODS We have analyzed the data collected from press releases and follow-ups published daily by the Ministry of Health, we have studied the possible correlations of these data with certain events or decisions having a possible impact on their development, such as confinement at home and its reduction, the prescription of hydroxychloroquine/azithromycin combination for serious patients and its extension to all positive COVID subjects. Results are presented in graphics, the data collection was closed on 31/05/2020. RESULTS Covid-19 pandemic spreads from February 25, 2020, when a foreign citizen is tested positive, on March 1 a cluster is formed in the city of Blida where sixteen members of the same family are infected during a wedding party. Wilaya of Blida becomes the epicentre of coronavirus epidemic in Algeria and lockdown measures taken, while the number of national cases diagnosed begins to increases In any event, the association of early containment measures combined with a generalized initial treatment for all positive cases, whatever their degree of severity, will have contributed to a reduction in the fatality rate of COVID 19 and a slowing down of its doubling time. CONCLUSIONS In Algeria, the rapid combination of rigorous containment measure at home and early generalized treatment with hydroxychloroquin have demonstrated their effectiveness in terms of morbidity and mortality, the classic measures of social distancing and hygiene will make it possible to perpetuate these results by reducing viral transmission, the only unknown, the reopening procedure which can only be started after being surrounded by precautions aimed at ensuring the understanding of the population. CLINICALTRIAL Algeria, Covid-19, pandemic, hydroxychloroquin, azithromycin, case fatality rate

scholarly journals Author Correction: Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Lei-Ke Zhang ◽  
Yuan Sun ◽  
Haolong Zeng ◽  
Qingxing Wang ◽  
Xiaming Jiang ◽  
...  
Keyword(s):  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
Case Fatality Rate ◽  
Channel Blocker ◽  
Case Fatality ◽  
Fatality Rate ◽  
Amlodipine Besylate

A Correction to this paper has been published: https://doi.org/10.1038/s41421-021-00267-0

Sign in / Sign up

Export Citation Format

Share Document